These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19199991)

  • 1. Multivalent-based drug design applied to serotonin 5-HT(4) receptor oligomers.
    Lezoualc'h F; Jockers R; Berque-Bestel I
    Curr Pharm Des; 2009; 15(6):719-29. PubMed ID: 19199991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of specific bivalent probes that functionally interact with 5-HT(4) receptor dimers.
    Russo O; Berthouze M; Giner M; Soulier JL; Rivail L; Sicsic S; Lezoualc'h F; Jockers R; Berque-Bestel I
    J Med Chem; 2007 Sep; 50(18):4482-92. PubMed ID: 17676726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of specific probes for human 5-HT4 receptor dimerization studies.
    Soulier JL; Russo O; Giner M; Rivail L; Berthouze M; Ongeri S; Maigret B; Fischmeister R; Lezoualc'h F; Sicsic S; Berque-Bestel I
    J Med Chem; 2005 Oct; 48(20):6220-8. PubMed ID: 16190749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalent ligands as specific pharmacological tools for G protein-coupled receptor dimers.
    Berque-Bestel I; Lezoualc'h F; Jockers R
    Curr Drug Discov Technol; 2008 Dec; 5(4):312-8. PubMed ID: 19075611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of multivalent ligand targeting G-protein-coupled receptors.
    Liu Z; Zhang J; Zhang A
    Curr Pharm Des; 2009; 15(6):682-718. PubMed ID: 19199990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric properties of G protein-coupled receptor oligomers.
    Springael JY; Urizar E; Costagliola S; Vassart G; Parmentier M
    Pharmacol Ther; 2007 Sep; 115(3):410-8. PubMed ID: 17655934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of G protein-coupled receptors dimerization: From bivalent ligands to drug-like small molecules.
    Qian M; Sun Z; Chen X; Van Calenbergh S
    Bioorg Chem; 2023 Nov; 140():106809. PubMed ID: 37651896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G protein activation by serotonin type 4 receptor dimers: evidence that turning on two protomers is more efficient.
    Pellissier LP; Barthet G; Gaven F; Cassier E; Trinquet E; Pin JP; Marin P; Dumuis A; Bockaert J; Banères JL; Claeysen S
    J Biol Chem; 2011 Mar; 286(12):9985-97. PubMed ID: 21247891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT4 receptors.
    Bockaert J; Claeysen S; Compan V; Dumuis A
    Curr Drug Targets CNS Neurol Disord; 2004 Feb; 3(1):39-51. PubMed ID: 14965243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic modulators of the serotonin 5-HT
    Lanthier C; Dallemagne P; Lecoutey C; Claeysen S; Rochais C
    Expert Opin Ther Pat; 2020 Jul; 30(7):495-508. PubMed ID: 32400221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands.
    Hiller C; Kühhorn J; Gmeiner P
    J Med Chem; 2013 Sep; 56(17):6542-59. PubMed ID: 23678887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional significance of serotonin receptor dimerization.
    Herrick-Davis K
    Exp Brain Res; 2013 Oct; 230(4):375-86. PubMed ID: 23811735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPCR dimers fall apart.
    Lambert NA
    Sci Signal; 2010 Mar; 3(115):pe12. PubMed ID: 20354223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of bivalent ligands targeting putative GPCR dimers.
    Huang B; St Onge CM; Ma H; Zhang Y
    Drug Discov Today; 2021 Jan; 26(1):189-199. PubMed ID: 33075471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in elucidating the structural and dynamic character of G Protein-Coupled Receptor oligomers for use in drug discovery.
    Bortolato A; Mobarec JC; Provasi D; Filizola M
    Curr Pharm Des; 2009; 15(35):4017-25. PubMed ID: 20028319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic opportunities for 5-HT
    Maroteaux L; Ayme-Dietrich E; Aubertin-Kirch G; Banas S; Quentin E; Lawson R; Monassier L
    Pharmacol Ther; 2017 Feb; 170():14-36. PubMed ID: 27771435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
    Carli M; Kolachalam S; Aringhieri S; Rossi M; Giovannini L; Maggio R; Scarselli M
    Curr Neuropharmacol; 2018 Jan; 16(2):222-230. PubMed ID: 28521704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.
    Brudeli B; Moltzau LR; Andressen KW; Krobert KA; Klaveness J; Levy FO
    Bioorg Med Chem; 2010 Dec; 18(24):8600-13. PubMed ID: 21075638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two transmembrane Cys residues are involved in 5-HT4 receptor dimerization.
    Berthouze M; Rivail L; Lucas A; Ayoub MA; Russo O; Sicsic S; Fischmeister R; Berque-Bestel I; Jockers R; Lezoualc'h F
    Biochem Biophys Res Commun; 2007 May; 356(3):642-7. PubMed ID: 17379184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multivalent ligand: design principle for targeted therapeutic delivery approach.
    Chittasupho C
    Ther Deliv; 2012 Oct; 3(10):1171-87. PubMed ID: 23116010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.